Oruka Therapeutics, Inc. ORKA Investments - Amortized Cost Basis

Investments - Amortized Cost Basis at other companies

AmgenAMGN

——

AbbVieABBV

——

Arcutis Biotherapeutics, Inc.ARQT

——

Spyre Therapeutics, Inc.SYRE

——

Arcus BiosciencesRCUS

——

Regeneron PharmaceuticalsREGN

——

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s investments - amortized cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s investments - amortized cost basis?: Oruka Therapeutics, Inc. (ORKA) reported investments - amortized cost basis of $492.33M in Q1 2026.
How has Oruka Therapeutics, Inc.'s investments - amortized cost basis changed year-over-year?: Oruka Therapeutics, Inc.'s investments - amortized cost basis increased by 33.5% year-over-year, from $368.84M to $492.33M.